CYP26A1 and colorectal carcinoma: This suggests that decreasing the intracellular metabolism of ATRA using agents that inhibit CYP26A1 activity may increase ATRA levels and therapeutically augment RA signaling, leading to decreased CSC numbers in APC-mutant CRC tissues [16].